WO2007095389A3 - Treatment of hyperproliferative diseases with camptothecine n-oxide and analogs - Google Patents
Treatment of hyperproliferative diseases with camptothecine n-oxide and analogs Download PDFInfo
- Publication number
- WO2007095389A3 WO2007095389A3 PCT/US2007/004253 US2007004253W WO2007095389A3 WO 2007095389 A3 WO2007095389 A3 WO 2007095389A3 US 2007004253 W US2007004253 W US 2007004253W WO 2007095389 A3 WO2007095389 A3 WO 2007095389A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analogs
- oxides
- camptothecine
- oxide
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention relates to N-oxides of camptothecin analogs having activity for treating hyperproliferative disorders. Pharmaceutical compositions comprising therapeutically effective amount of camptothecin analog N-oxides and bis N-oxides, or a pharmaceutically acceptable salt or prodrug thereof, are disclosed. Further, the invention relates to methods of using the compounds, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77423506P | 2006-02-17 | 2006-02-17 | |
US60/774,235 | 2006-02-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007095389A2 WO2007095389A2 (en) | 2007-08-23 |
WO2007095389A3 true WO2007095389A3 (en) | 2009-02-19 |
Family
ID=38372166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/004253 WO2007095389A2 (en) | 2006-02-17 | 2007-02-20 | Treatment of hyperproliferative diseases with camptothecine n-oxide and analogs |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007095389A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011064152A1 (en) * | 2009-11-26 | 2011-06-03 | Universität Bern Verwaltungsdirektion | Inhibitors of topoisomerase i for the treatment of autoimmune diseases |
CN102477042A (en) * | 2010-11-26 | 2012-05-30 | 复旦大学 | 10-hydroxyamptothecin derivative, and its preparation method and application |
CN102850400A (en) | 2011-06-30 | 2013-01-02 | 周文强 | Camptothecin derivative, and preparation method, pharmaceutical composition and use thereof |
KR101371354B1 (en) | 2012-02-29 | 2014-03-10 | 한국식품연구원 | Composition for prevention and treatment of obesity or metabolic diseases comprising 10-hydroxycamptothecin |
CN103113381B (en) * | 2013-02-26 | 2014-12-10 | 大连理工大学 | Serial water-soluble hydroxycamptothecine naphthenic amino alcohol derivative and preparation method and use thereof |
US20160375042A1 (en) * | 2014-01-28 | 2016-12-29 | Wenqiang Zhou | Use of camptothecin derivative in preparing pharmaceutical used for treating multiple myeloma |
CN106588946B (en) * | 2017-01-25 | 2019-01-22 | 郑州大学 | 10-hydroxycamptothecine derivative, synthetic method and its application |
CA3111403A1 (en) * | 2018-09-17 | 2020-03-26 | Canget Biotekpharma | Matter of composition, synthesis, formulation and application of fl118 platform positions 7 and 9-derived analogues for treatment of human disease |
CN109575044A (en) * | 2018-12-21 | 2019-04-05 | 西安交通大学 | 2-(camptothecine -10- oxygroup) acetamides and application |
WO2021173773A1 (en) | 2020-02-25 | 2021-09-02 | Mediboston, Inc. | Camptothecin derivatives and conjugates thereof |
CN113880855A (en) * | 2021-09-02 | 2022-01-04 | 兰州大学 | Preparation of 9-fluoro camptothecin derivative and application of 9-fluoro camptothecin derivative in anti-tumor aspect |
CN117599058A (en) * | 2023-03-09 | 2024-02-27 | 兰州大学 | Application of camptothecine derivatives in preparation of medicines for treating bladder cancer |
CN116444542A (en) * | 2023-03-31 | 2023-07-18 | 广州医科大学 | Thiophene-phenothiazine compound, synthesis method thereof and application thereof in preparation of phototherapy drugs |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4513138A (en) * | 1981-09-04 | 1985-04-23 | Kabushiki Kaisha Yakult Honsha | Camptothecin-1-oxide derivatives |
US6306868B1 (en) * | 1996-02-23 | 2001-10-23 | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori | Methods for inhibiting the growth of tumors with 7-substituted camptothecin derivatives |
-
2007
- 2007-02-20 WO PCT/US2007/004253 patent/WO2007095389A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4513138A (en) * | 1981-09-04 | 1985-04-23 | Kabushiki Kaisha Yakult Honsha | Camptothecin-1-oxide derivatives |
US6306868B1 (en) * | 1996-02-23 | 2001-10-23 | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori | Methods for inhibiting the growth of tumors with 7-substituted camptothecin derivatives |
Also Published As
Publication number | Publication date |
---|---|
WO2007095389A2 (en) | 2007-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007095389A3 (en) | Treatment of hyperproliferative diseases with camptothecine n-oxide and analogs | |
WO2007098091A3 (en) | Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs | |
WO2007098089A3 (en) | Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs | |
WO2010150995A3 (en) | Compositions for treating drug addiction and improving addiction-related behavior | |
WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
EP2562177A3 (en) | Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof | |
WO2006098603A3 (en) | Composition comprising isoorientin for suppressing histamine | |
TN2009000137A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
WO2007100675A3 (en) | Collagenase for treating cellulite | |
WO2005070930A3 (en) | Tetrahydrocarboline compounds as anticancer agents | |
TW200621730A (en) | Chemical compounds | |
WO2005115432A3 (en) | Treatment of ocular diseases and disorders using lantibiotic compositions | |
MX2010005631A (en) | Novel cyclic hydrocarbon compounds for the treatment of diseases. | |
WO2008011174A3 (en) | Jak inhibitors for treatment of myeloproliferative disorders | |
WO2007112000A3 (en) | Treatment of pain | |
WO2005092009A3 (en) | Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders | |
WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
WO2009091550A8 (en) | Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis | |
WO2008002514A3 (en) | Combination cough treatment compounds and method of treating common coughs | |
WO2007121088A3 (en) | Combinations of therapeutic agents for treating cancer | |
WO2007123511A3 (en) | Dosing regimens for the treatment of cancer | |
WO2006086693A3 (en) | Medical devices | |
WO2006002096A3 (en) | Low doses of l-citrulline for treating diseases | |
WO2013085849A3 (en) | Sulfate esters of noribogaine | |
WO2007095056A3 (en) | Slow intraventricular delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07751042 Country of ref document: EP Kind code of ref document: A2 |